Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | VDR | P11473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991311 | 0.86 | CYP1A2 (0.53) | SMN1; SMN2AKR1C2AKR1C1ALDH1A1MAPT | |
| SCHEMBL15630993 | 0.86 | AKR1C2 (0.53) | GCGSMN1; SMN2AKR1C2AKR1C1MAPT | |
| SCHEMBL1468345 | 0.83 | LMNA (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12284352 | 0.83 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13753322 | 0.82 | AKR1C2 (0.51) | SMN1; SMN2AKR1C2AKR1C1ALDH1A1MAPT | |
| SCHEMBL9251399 | 0.82 | HCAR3 (0.64) | SMN1; SMN2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL20742960 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2AKR1C2AKR1C1ALDH1A1MAPT | |
| SCHEMBL7399156 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2AKR1C2AKR1C1ALDH1A1MAPT | |
| SCHEMBL9248878 | 0.80 | HCAR3 (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3991305 | 0.80 | AKR1C2 (0.49) | SMN1; SMN2AKR1C2AKR1C1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCG 7/4885SMN1; SMN2 4508/4885SIRT5 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.